Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
June 14, 2022 09:00 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
May 25, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Delivered first clinical data demonstrating target engagement and translation of PN chemistry’s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9 clinical trial to optimize dose level and...
Wave Life Sciences to Present at Upcoming Investor Conferences
May 10, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022
May 05, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD
April 25, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional variants and poly(GP) dipeptide repeat proteins in mice for at least six...
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 19, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004
April 04, 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment groups after single doses Extending dose observation period from three months (day 85) to...
Wave Life Sciences to Present at Stifel 2022 CNS Days
March 21, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings
March 15, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
Presentation at OPT 2022 to highlight AATD program, including reduction of liver aggregates with repeat AIMer dosing out to 19 weeks Multiple presentations and panel discussions at 3rd Annual RNA...